AAPG Stock — Ascentage Pharma Group International

Ascentage Pharma Group International (AAPG)

Updated October 6, 2026.

AAPG is a Stock. Total return is -7.4% over the past 1.7 years, 38.1 points behind SPY at 30.7%.

Ascentage Pharma Group International is a clinical-stage biotechnology company developing therapies for cancers, chronic hepatitis B, and age-related diseases, primarily in Mainland China. Its pipeline includes several small-molecule drug candidates targeting various oncology indications and viral infections, supported by partnerships with research institutions and Peking University. The company does not currently have an established distribution schedule.

AAPG performance versus SPY

Price and return data through 2026-10-06.

Total return is -7.4% over the past 1.7 years, 38.1 points behind SPY at 30.7%. Over the past year its total return — price change plus distributions reinvested — is -59.6%. Its deepest 1-year drawdown was 63.7%.

AAPG key facts

Asset type

Stock

Asset class

Equity

Inception date

01/24/2025

Distribution frequency

None

Last close

$16.09 (stale; as of 2026-10-06)

Market cap

$1,502,628,077

Average volume

14340.0

Beta

0.669

Payout ratio

0.0%

Forward P/E

10.0604

EPS

$-2.31

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) is the latest regular payout annualized by the fund's stated frequency, divided by the last close. Issuers often publish this as “Distribution Rate” on the fact sheet. Trailing-12-month yield is the sum of distributions paid in the last 12 months, split-adjusted, divided by the last close. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

AAPG risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 63.7%.

Who may consider AAPG — and who may not

It is a weaker fit for investors who need monthly cash flow (AAPG does not currently distribute); investors hunting double-digit covered-call yields; investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

Frequently asked questions